Cronkhite-Canada Syndrome Medication

  • Author: Agnieszka B Serwin, MD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 24, 2012
 

Medication Summary

In described cases of Cronkhite-Canada syndrome, drugs used include corticosteroids, mesalamine (also know as mesalazine or 5-aminosalicylic acid),[29] and antibiotics (ie, tetracycline, metronidazole). H1- and H2-receptor blockers have been used. Therapy with antiplasmin agents has also been reported. These agents interfere with fibrinolysis in the gastrointestinal tract, thereby reducing the loss of proteins.

Next

Corticosteroids

Class Summary

Inhibits inflammation within gastrointestinal mucosa.

View full drug information

Prednisone (Deltasone)

 

Used as immunosuppressant to treat immune disorders. Decreases inflammatory reaction by reversing increased capillary permeability and inhibits antigen-antibody binding.

Previous
Next

Antibiotics

Class Summary

Used for the concomitant bacterial overgrowth within gastrointestinal mucosa.

View full drug information

Tetracycline (Sumycin)

 

Treats gram-positive and gram-negative organisms and mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and, possibly, 50S ribosomal subunit(s).

View full drug information

Metronidazole (Flagyl)

 

Used to inhibit the concomitant bacterial overgrowth within gastrointestinal mucosa. Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for C difficile enterocolitis).

Previous
Next

Histamine H2 blockers

Class Summary

An increased gastric acid secretion is found in some patients with Cronkhite-Canada syndrome.

View full drug information

Ranitidine (Zantac)

 

Inhibits histamine stimulation of the H2 receptor in gastric parietal cells, which, in turn, reduces gastric acid secretion, gastric volume, and reduced hydrogen concentrations.

Previous
Next

Anti-inflammatories

Class Summary

Inhibit inflammatory lesions within gastrointestinal mucosa.

View full drug information

Mesalamine (Rowasa, Asacol, Pentasa)

 

Reduces production of nitric oxide and superoxides and regulatory effect on leukotriene B4 results in inhibition of inflammation in gastrointestinal tract. Treats mildly to moderately active ulcerative colitis. Usual course of therapy in adults is 3-6 wk. Some patients may need concurrent rectal and oral therapy.

Previous
Next

Proton pump inhibitors

View full drug information

Omeprazole (Prilosec)

 

Decreases gastric acid secretion by inhibiting the parietal cell H+/K+ -ATPase pump. Indicated for gastric ulcers, duodenal ulcers, GERD, erosive esophagitis, and eradication of H pylori when combined with other medications.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Agnieszka B Serwin, MD  Consulting Staff, Department of Dermatology and Venereology, Medical Academy of Bialystok, Poland

Disclosure: Nothing to disclose.

Coauthor(s)

Hanna Mysliwiec, MD  Staff Physician, Department of Dermatology and Venereology, Medical Academy of Bialystok, Poland

Disclosure: Nothing to disclose.

Specialty Editor Board

Franklin Flowers, MD  Chief, Division of Dermatology, Professor, Department of Medicine and Otolaryngology, Affiliate Associate Professor of Pediatrics and Pathology, University of Florida College of Medicine

Franklin Flowers, MD, is a member of the following medical societies: American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Cronkhite LW Jr, Canada WJ. Generalized gastrointestinal polyposis; an unusual syndrome of polyposis, pigmentation, alopecia and onychotrophia. N Engl J Med. Jun 16 1955;252(24):1011-5. [Medline].

  2. Ho V, Banney L, Falhammar H. Hyperpigmentation, nail dystrophy and alopecia with generalised intestinal polyposis: Cronkhite-Canada syndrome. Australas J Dermatol. Nov 2008;49(4):223-5. [Medline].

  3. Daniel ES, Ludwig SL, Lewin KJ, Ruprecht RM, Rajacich GM, Schwabe AD. The Cronkhite-Canada Syndrome. An analysis of clinical and pathologic features and therapy in 55 patients. Medicine (Baltimore). Sep 1982;61(5):293-309. [Medline].

  4. Negoro K, Takahashi S, Kinouchi Y, et al. Analysis of the PTEN gene mutation in polyposis syndromes and sporadic gastrointestinal tumors in Japanese patients. Dis Colon Rectum. Oct 2000;43(10 Suppl):S29-33. [Medline].

  5. Senesse P, Justrabo E, Boschi F, et al. [Cronkhite-Canada syndrome and arsenic poisoning: fortuitous association or new etiological hypothesis?]. Gastroenterol Clin Biol. Mar 1999;23(3):399-402. [Medline].

  6. Murata I, Yoshikawa I, Endo M, et al. Cronkhite-Canada syndrome: report of two cases. J Gastroenterol. 2000;35(9):706-11. [Medline].

  7. Sweetser S, Ahlquist DA, Osborn NK, Sanderson SO, Smyrk TC, Chari ST, et al. Clinicopathologic Features and Treatment Outcomes in Cronkhite-Canada Syndrome: Support for Autoimmunity. Dig Dis Sci. Sep 1 2011;[Medline].

  8. de Silva DG, Fernando AD, Law FM, Premarathne M, Liyanarachchi DS. Infantile Cronkhite-Canada syndrome. Indian J Pediatr. Mar-Apr 1997;64(2):261-6. [Medline].

  9. Devulder F, Bouche O, Diebold MD, et al. [Cronkhite-Canada syndrome: a new French case]. Gastroenterol Clin Biol. Mar 1999;23(3):407-8. [Medline].

  10. Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch. Dec 2000;437(6):581-90. [Medline].

  11. Vernia P, Marcheggiano A, Marinaro V, Morabito S, Guzzo I, Pierucci A. Is Cronkhite-Canada Syndrome necessarily a late-onset disease?. Eur J Gastroenterol Hepatol. Oct 2005;17(10):1139-41. [Medline].

  12. Yasuda T, Ueda T, Matsumoto I, Shirasaka D, Nakajima T, Sawa H, et al. Cronkhite-Canada syndrome presenting as recurrent severe acute pancreatitis. Gastrointest Endosc. Mar 2008;67(3):570-2. [Medline].

  13. Naoshima-Ishibashi Y, Murofushi T. A case of Cronkhite-Canada syndrome with vestibular disturbances. Eur Arch Otorhinolaryngol. Nov 2004;261(10):558-9. [Medline].

  14. Sweetser S, Alexander GL, Boardman LA. A case of Cronkhite-Canada syndrome presenting with adenomatous and inflammatory colon polyps. Nat Rev Gastroenterol Hepatol. Aug 2010;7(8):460-4. [Medline].

  15. Bruce A, Ng CS, Wolfsen HC, Smallridge RC, Lookingbill DP. Cutaneous clues to Cronkhite-Canada syndrome: a case report. Arch Dermatol. Feb 1999;135(2):212. [Medline].

  16. Yashiro M, Kobayashi H, Kubo N, Nishiguchi Y, Wakasa K, Hirakawa K. Cronkhite-Canada syndrome containing colon cancer and serrated adenoma lesions. Digestion. 2004;69(1):57-62. [Medline].

  17. Hutnik CM, Nichols BD. Cataracts in systemic diseases and syndromes. Curr Opin Ophthalmol. Feb 1999;10(1):22-8. [Medline].

  18. Peitl A, Vucic Peitl M, Pavlovic E, Ljubicic D. Acute brain syndrome as a consequence of the Cronkhite-Canada syndrome. Psychiatr Danub. Jun 2005;17(1-2):90-3. [Medline].

  19. Nakayama M, Muta H, Somada S, et al. Cronkhite-Canada syndrome associated with schizophrenia. Intern Med. 2007;46(4):175-80. [Medline].

  20. Kim MS, Jung HK, Jung HS, et al. [A Case of Cronkhite-Canada syndrome showing resolution with Helicobacter pylori eradication and omeprazole]. Korean J Gastroenterol. Jan 2006;47(1):59-64. [Medline].

  21. Hanzawa M, Yoshikawa N, Tezuka T, et al. Surgical treatment of Cronkhite-Canada syndrome associated with protein-losing enteropathy: report of a case. Dis Colon Rectum. Jul 1998;41(7):932-4. [Medline].

  22. Bacher T, Schonekas H, Steurer KT, Wunsch PH. [The Cronkhite-Canada Syndrome. A rare differential diagnosis of generalized gastrointestinal polyposis]. Dtsch Med Wochenschr. May 23 1997;122(21):676-81. [Medline].

  23. Cao XC, Wang BM, Han ZC. Wireless capsule endoscopic finding in Cronkhite-Canada syndrome. Gut. Jun 2006;55(6):899-900. [Medline].

  24. Ikeda K, Sannohe Y, Murayama H. A case of Cronkhite-Canada syndrome developing after hemi-colectomy. Endoscopy. Nov 1981;13(6):251-3. [Medline].

  25. Nagata K, Sato Y, Endo S, Kudo SE, Kushihashi T, Umesato K. CT endoscopy for the follow-up of Cronkhite-Canada syndrome. Int J Colorectal Dis. Sep 2007;22(9):1131-2. [Medline].

  26. Okamoto K, Isomoto H, Shikuwa S, Nishiyama H, Ito M, Kohno S. A case of Cronkhite-Canada syndrome: remission after treatment with anti-Helicobacter pylori regimen. Digestion. 2008;78(2-3):82-7. [Medline].

  27. Burke AP, Sobin LH. The pathology of Cronkhite-Canada polyps. A comparison to juvenile polyposis. Am J Surg Pathol. Nov 1989;13(11):940-6. [Medline].

  28. Allbritton J, Simmons-O'Brien E, Hutcheons D, Whitmore SE. Cronkhite-Canada syndrome: report of two cases, biopsy findings in the associated alopecia, and a new treatment option. Cutis. Apr 1998;61(4):229-32. [Medline].

  29. Takahura M, Adachi H, Tsuchihashi N. A case of Cronkhite-Canada Syndrome markedly improved with mesalazine therapy. Digest Endos. 2004;16:74-8.

  30. Sampson JE, Harmon ML, Cushman M, Krawitt EL. Corticosteroid-responsive Cronkhite-Canada syndrome complicated by thrombosis. Dig Dis Sci. Apr 2007;52(4):1137-40. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.